Physician profile
David E Kim
NPI 1508959750
$11,603.17
in general payments reported to CMS, 2019-2025
45 companies · $1,750 in 2025
The $1,750 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,298 · 2020: $1,331 · 2021: $1,919 · 2022: $1,716 · 2023: $1,840 · 2024: $1,749 · 2025: $1,750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,339.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,792.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,537.35 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,099.40 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $784.49 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $760.87 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $648.21 | 2019-2025 | |
| Corcept Therapeutics | $497.36 | 2023-2025 | Korlym |
| Exact Sciences Corporation | $402.20 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $342.97 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.84 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $285.12 | 2021-2023 | |
| Axsome Therapeutics, INC. | $278.32 | 2023-2025 | Auvelity |
| Esperion Therapeutics, INC. | $248.86 | 2020-2025 | Nexletol |
| Ardelyx, INC. | $243.64 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $241.68 | 2019-2023 | Belsomra |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.